These guidelines will be updated every four years. Vascular centres are encouraged to audit
implementations made as a result of the guidelines. Audit cycles should be repeated and …

The availability of over-the-counter (OTC) proton pump inhibitors (PPIs) for the short-term (2
weeks) management of frequent heartburn (≥ 2 days/week) has increased markedly, yet …

BACKGROUND: Uncertainty regarding clopidogrel effectiveness attenuation because of a
drug-drug interaction with proton pump inhibitors (PPI) has led to conflicting guidelines on …

Objective The aim of this study was to determine the extent of drug interactions affecting
levothyroxine, using study drugs often co‐administered to patients on long‐term …

This study compared proton pump inhibitors (PPIs) and histamine H2 receptor antagonists
(H2RAs) for prevention of low-dose aspirin (LDA)-related gastrointestinal (GI) erosion, ulcer …

Drug–drug interaction between antiacid and antiplatelet agents has not been fully
elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in …

Background Proton pump inhibitors (PPI s) have been shown to be carcinogenic in rodent
studies. Aim As part of a long‐term post‐marketing surveillance study requested by the US …

Objectives To determine the pharmacodynamics and pharmacokinetics of rivaroxaban
(RVX), in healthy cats and to evaluate the clinicopathologic effects of various plasma RVX …

Objectives: Mitigating the gastrointestinal (GI) bleeding risks of dual antiplatelet therapy
(DAPT) is a common clinical concern. While proton pump inhibitors (PPIs) remain the most …

Background Concomitant use of proton-pump inhibitors (PPIs) has been implicated in
diminished antiplatelet response to clopidogrel and an increased risk of ischemic events, but …